A phase III trial of epitinib in first-line patients with EGFR-mutant NSCLC patients with brain metastasis

Trial Profile

A phase III trial of epitinib in first-line patients with EGFR-mutant NSCLC patients with brain metastasis

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Mar 2018

At a glance

  • Drugs Epitinib (Primary)
  • Indications Brain metastases; Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Chi-Med
  • Most Recent Events

    • 06 Mar 2018 According to a Chi-Med media release, the company is preparing to initiate this pivotal study of epitinib in EGFR mutant NSCLC patients with brain metastasis in China in 2018.
    • 18 Aug 2016 New trial record
    • 02 Aug 2016 According to Chi-Med media release, company targets to initiate this pivotal registration study before the end of H1 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top